시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 류마티스성 다발근통 시장 보고서(2025년)
Polymyalgia Rheumatica Global Market Report 2025
상품코드 : 1730995
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 류마티스성 다발근통 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간중의 성장은 생물제제 채용 확대, 정밀 의료 확대, 의약품 승인의 신속화, 상환의 확대, 임상시험의 확대가 견인할 것으로 보입니다.

맞춤형 의료에 대한 수요 증가가 향후의 류마티스성 다발 근통 시장의 성장을 견인할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전적 프로파일, 라이프 스타일, 특정의 건강 상태에 맞추어 커스터마이즈된 치료를 실시해, 보다 효과적인 결과를 인도하는 것입니다. 유전적 연구를 통해, 유전적 변이에 대한 이해가 깊어짐으로써, 특정의 유전자 마커를 표적으로 한 치료가 가능하게 되었습니다. 2024년 2월, 미국을 거점으로 하는 단체인 Personalized Medicine Coalition은 FDA가 2023년에 희귀질환에 대한 새로운 맞춤형 치료를 16건 승인하고, 2022년 6건에서 증가했다고 보고했습니다.

또한 원격 의료 서비스의 성장도 류마티스성 다발근통 시장의 성장에 기여할 것으로 보입니다. 이 서비스는 증상의 원격 모니터링, 복용 관리 및 정기적인 후속 조치를 허용하여 류마티스성 다발근통(PMR)을 관리하는 데 도움이 됩니다. 호주 통계국에 따르면, 2022-23년에는 87.7%의 사람이 원격 의료 상담을 이용했으며, 이 숫자는 2023-24년에는 89.2%로 상승했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Polymyalgia rheumatica (PMR) is an inflammatory condition that primarily affects older adults, leading to muscle pain and stiffness, especially in the shoulders, hips, and neck. It is characterized by aching and swelling in the muscles around the shoulders and hips, making it difficult to move and perform daily activities.

The primary treatment types for polymyalgia rheumatica include corticosteroids, nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and biologics. Corticosteroids are the most common treatment for PMR, helping to reduce inflammation and relieve symptoms by mimicking adrenal hormones. These medications can be administered orally, intravenously, or subcutaneously, and they are used for various patient types, including adults, geriatrics, and pediatrics. Distribution occurs through different channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The polymyalgia rheumatica market research report is one of a series of new reports from The Business Research Company that provides polymyalgia rheumatica market statistics, including the polymyalgia rheumatica industry global market size, regional shares, competitors with the polymyalgia rheumatica market share, detailed polymyalgia rheumatica market segments, market trends, and opportunities, and any further data you may need to thrive in the polymyalgia rheumatica industry. This polymyalgia rheumatica market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The polymyalgia rheumatica market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historical period can be attributed to factors such as increasing awareness among healthcare practitioners, the rising use of corticosteroids, the growth of specialty clinics, the introduction of biologic therapies, and increased healthcare budgets.

The polymyalgia rheumatica market size is expected to see strong growth in the next few years. It will grow to $1.73 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period is expected to be driven by the growing adoption of biologics, the expansion of precision medicine, accelerated drug approvals, broader reimbursements, and the expansion of clinical trials. Key trends for the forecast period include the development of combination therapies, advancements in personalized medicine, the growth of precision medicine, the integration of electronic health records, and improvements in biomarkers.

The increasing demand for personalized medicine is expected to drive the growth of the polymyalgia rheumatica market in the future. Personalized medicine involves medical treatments customized to an individual's genetic profile, lifestyle, and specific health conditions, leading to more effective outcomes. The demand for this approach is fueled by advancements in genetic research, growing patient expectations for tailored treatments, and improvements in diagnostic technologies. Through genetic research, a better understanding of genetic variations has allowed for treatments that target specific genetic markers. Personalized medicine helps identify the most effective drugs based on a patient's characteristics, leading to safer and more efficient treatment plans. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. This growth in personalized medicine is driving the expansion of the polymyalgia rheumatica market.

The growth of telemedicine services is also expected to contribute to the growth of the polymyalgia rheumatica market. Telemedicine leverages digital communication technologies such as video calls, phone calls, and online messaging to offer remote medical consultations, diagnoses, treatments, and follow-up care, eliminating the need for in-person visits. The rise in telemedicine is driven by increasing demand for convenient healthcare options and cost-effective solutions. Patients, particularly for non-urgent consultations, are seeking more convenient alternatives that telemedicine offers. These services help manage polymyalgia rheumatica (PMR) by enabling remote monitoring of symptoms, medication management, and regular follow-ups, all essential for controlling chronic pain and inflammation. For instance, according to the Australian Bureau of Statistics, in 2022-23, 87.7% of people used telehealth consultations, and this figure rose to 89.2% in 2023-24. Thus, the growth of telemedicine is fueling the expansion of the polymyalgia rheumatica market.

Major companies are focusing on developing advanced drugs, such as interleukin-6 (IL-6) receptor blockers, to offer more targeted and effective treatment options. IL-6 receptor blockers are biological drugs that target IL-6, a pro-inflammatory cytokine involved in autoimmune diseases. By blocking IL-6, these drugs help reduce inflammation and alleviate symptoms, thus improving the quality of life for PMR patients. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, announced that the FDA approved Kevzara (sarilumab) for treating polymyalgia rheumatica in adults who have not responded to corticosteroids or cannot tolerate tapering off them. Kevzara is the first and only biologic approved for this condition, and it works by inhibiting IL-6 signaling. In a study, 28.3% of patients treated with sarilumab achieved sustained remission after 52 weeks, compared to 10.3% of those on a placebo. Kevzara is administered via subcutaneous injection every two weeks and is also approved for moderately to severely active rheumatoid arthritis. Sanofi's stock (SNY) is currently trading at $54.13 on NASDAQ.

Major players in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women's Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital.

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in polymyalgia rheumatica report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the polymyalgia rheumatica market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The polymyalgia rheumatica market consists of revenues earned by entities by providing services such as medication management, pain management, laboratory testing, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyalgia rheumatica market includes sales of disease-modifying anti-rheumatic drugs, calcium and vitamin D supplements, assistive devices, and physical therapy aids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Polymyalgia Rheumatica Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on polymyalgia rheumatica market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for polymyalgia rheumatica ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The polymyalgia rheumatica market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Polymyalgia Rheumatica Market Characteristics

3. Polymyalgia Rheumatica Market Trends And Strategies

4. Polymyalgia Rheumatica Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Polymyalgia Rheumatica Growth Analysis And Strategic Analysis Framework

6. Polymyalgia Rheumatica Market Segmentation

7. Polymyalgia Rheumatica Market Regional And Country Analysis

8. Asia-Pacific Polymyalgia Rheumatica Market

9. China Polymyalgia Rheumatica Market

10. India Polymyalgia Rheumatica Market

11. Japan Polymyalgia Rheumatica Market

12. Australia Polymyalgia Rheumatica Market

13. Indonesia Polymyalgia Rheumatica Market

14. South Korea Polymyalgia Rheumatica Market

15. Western Europe Polymyalgia Rheumatica Market

16. UK Polymyalgia Rheumatica Market

17. Germany Polymyalgia Rheumatica Market

18. France Polymyalgia Rheumatica Market

19. Italy Polymyalgia Rheumatica Market

20. Spain Polymyalgia Rheumatica Market

21. Eastern Europe Polymyalgia Rheumatica Market

22. Russia Polymyalgia Rheumatica Market

23. North America Polymyalgia Rheumatica Market

24. USA Polymyalgia Rheumatica Market

25. Canada Polymyalgia Rheumatica Market

26. South America Polymyalgia Rheumatica Market

27. Brazil Polymyalgia Rheumatica Market

28. Middle East Polymyalgia Rheumatica Market

29. Africa Polymyalgia Rheumatica Market

30. Polymyalgia Rheumatica Market Competitive Landscape And Company Profiles

31. Polymyalgia Rheumatica Market Other Major And Innovative Companies

32. Global Polymyalgia Rheumatica Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Polymyalgia Rheumatica Market

34. Recent Developments In The Polymyalgia Rheumatica Market

35. Polymyalgia Rheumatica Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기